Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$70.27 USD
+1.80 (2.63%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.27 USD
+1.80 (2.63%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
Edwards Lifesciences' (EW) SAPIEN 3 With Alterra Gets FDA Nod
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.
Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare
What History Shows Us About 2022 Market Returns
by Bryan Hayes
What to Expect From the Markets In 2022
Edwards (EW) States Long-Term Strategy, Provides 2022 View
by Zacks Equity Research
Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong third-quarter results and bullish 2021 guidance.
Edwards Lifesciences (EW) Beats on Q3 Earnings, Gross Margin Up
by Zacks Equity Research
Strong sales growth across all four products group along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) third-quarter revenues.
Edwards Lifesciences (EW) Tops Q3 Earnings Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.89% and -0.92%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.
OCPNY or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Edwards Lifesciences, DexCom, Twitter, Cigna Corp and Restaurant Brands
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Edwards Lifesciences, DexCom, Twitter, Cigna Corp and Restaurant Brands
Top Analyst Reports for Edwards Lifesciences, DexCom & Twitter
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Edwards Lifesciences Corporation (EW), DexCom, Inc. (DXCM), and Twitter, Inc. (TWTR).
Edwards Lifesciences (EW) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Improvement in Critical Care and Surgical Structural Heart businesses is expected to have contributed to Edwards Lifesciences' (EW) third-quarter results.
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable
by Zacks Equity Research
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.
The Zacks Analyst Blog Highlights: Facebook, AbbVie, 3M, Broadcom and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, AbbVie, 3M, Broadcom and Edwards Lifesciences
Top Analyst Reports for Facebook, AbbVie & 3M
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), AbbVie Inc. (ABBV), and 3M Company (MMM).
Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Top Research Reports for Costco, Altria & Edwards Lifesciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale (COST), Altria Group, Inc. (MO), and Edwards Lifesciences (EW).
3 Medical Instruments Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on base business recovery. ISRG, IDXX and ALC are set to gain the most. However, falling demand for COVID-19 tests might disrupt the trend.
Hill-Rom (HRC) Q3 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Hill-Rom (HRC) reports better-than-expected revenues for third-quarter fiscal 2021 with strong segmental performance driving the top line.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up
by Zacks Equity Research
Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.
Edwards Lifesciences (EW) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 16.36% and 7.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Edwards Lifesciences (EW) Ahead of Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.